Today: 13 March 2026
Subscribe
Browse Category

Stock Market 9 December 2025

Walmart (WMT) Stock on December 9, 2025: Nasdaq Debut, Tech Pivot and 2026 Outlook

Walmart (WMT) Stock on December 9, 2025: Nasdaq Debut, Tech Pivot and 2026 Outlook

Walmart began trading on the Nasdaq on December 9, 2025, after leaving the NYSE, with shares at $114–115 and a market cap near $910 billion. The stock trades at about 40 times earnings, well above the sector average, and sits just below its 52-week high. Over five years, Walmart has returned 131%, outpacing the S&P 500 by nearly 30 points. Analysts note the move could draw around $20 billion in new passive investment.
9 December 2025
··
Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson shares closed at $201.62 on December 8, 2025, up nearly 40% year to date and valuing the company at about $486 billion. The stock surged after a Q3 earnings beat, raised full-year guidance, and a surprise plan to spin off its DePuy Synthes orthopaedics unit. JNJ remains a key driver of recent Dow gains. Technical models project up to 16% further upside by March 2026.
9 December 2025
··
Salesforce (CRM) Stock on December 9, 2025: Q3 FY26 Beat, AI Agentforce Momentum and What Comes Next

Salesforce (CRM) Stock on December 9, 2025: Q3 FY26 Beat, AI Agentforce Momentum and What Comes Next

Salesforce shares traded near $260 on December 9, 2025, after reporting record Q3 results and raising its full-year outlook. The company posted Q3 revenue of about $10.3 billion, up 9% year-over-year, and adjusted EPS of $3.25, beating estimates. Market cap stood at roughly $243 billion. The stock remains about 25–30% lower for 2025 despite the recent rebound.
9 December 2025
···
Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma shares fell 4.2% to around $197.25 in late trading December 9 after a Q3 earnings miss and a three-month FDA review delay for its key dwarfism drug. Volume was about 76% below average. The company posted Q3 revenue of €213.6 million but reported a net loss of €61 million, mainly from finance expenses. Despite the pullback, ASND remains near its 52-week high and up year-on-year.
9 December 2025
··
BitMine Immersion Technologies (BMNR) Stock Soars as Ethereum Treasury Hits 3.86 Million ETH – Latest News, Forecasts and Risks (Dec. 9, 2025)

BitMine Immersion Technologies (BMNR) Stock Soars as Ethereum Treasury Hits 3.86 Million ETH – Latest News, Forecasts and Risks (Dec. 9, 2025)

BitMine Immersion Technologies shares jumped 8.4% to $38.85 intraday on December 9, 2025, after confirming control of 3.86 million ETH—over 3.2% of all Ethereum—and a $13.2 billion crypto and cash reserve. The company’s market cap stands at $14.8 billion with a trailing P/E of about 2.7. The stock traded between $34.66 and $39.25 during the session. Volume averaged 45 million shares over 30 days.
9 December 2025
····
KE Holdings (BEKE) Stock Slides as Buybacks Accelerate: What Q3 2025 Earnings and China’s Housing Slump Mean for Investors

KE Holdings (BEKE) Stock Slides as Buybacks Accelerate: What Q3 2025 Earnings and China’s Housing Slump Mean for Investors

KE Holdings (NYSE: BEKE) shares fell about 4.8% Tuesday, opening near $16.35 after closing at $17.08, with over 1 million shares traded. The drop came despite ongoing share buybacks and Q3 revenue rising 2.1% year-on-year to RMB 23.1 billion. Net income fell to RMB 747 million from RMB 1.17 billion a year earlier. BEKE underperformed even as international ETF VXUS saw strong inflows.
9 December 2025
····
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics shares traded at $17–18 on December 9, 2025, near the low end of their 52-week range of $15.55 to $36.91. The company’s lung cancer drug ivonescimab recently outperformed Keytruda in a limited trial, drawing attention but also regulatory questions. Summit granted inducement stock options to new hires on December 5. The company’s market cap stands near $13–14 billion.
9 December 2025
·
Credo Technology Group (CRDO) Stock: Earnings Blowout, AI Tailwinds, and What Comes Next

Credo Technology Group (CRDO) Stock: Earnings Blowout, AI Tailwinds, and What Comes Next

Credo Technology Group shares traded near $169 on December 9, 2025, down from a record $213.80 hit a week earlier after strong earnings. The company reported Q2 fiscal 2026 revenue of $268 million, far above estimates, and net income of $82.6 million versus a loss last year. Management raised Q3 guidance to $335–$345 million in revenue, citing demand from AI data centers.
9 December 2025
···
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.
9 December 2025
··
Ferguson Enterprises (FERG) Stock Slides After Q1 2026 Earnings – What Today’s Sell-Off Means for Investors

Ferguson Enterprises (FERG) Stock Slides After Q1 2026 Earnings – What Today’s Sell-Off Means for Investors

Ferguson Enterprises reported Q1 net sales of $8.17–8.2 billion, up 5.1% year-on-year, and adjusted diluted EPS of $2.84, up 15.9%. Shares fell sharply despite raised full-year guidance, as investors weighed valuations and growth forecasts. Residential revenue slipped 1%, while non-residential revenue jumped 12% on strong commercial demand. The company now targets 5% net sales growth for 2025.
9 December 2025
···
Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging shares fell to a new 52-week low near $14 on December 9, 2025, after the company cut its full-year earnings outlook and announced cost and production optimization measures. Trading volume topped 10 million shares. The company also confirmed a CEO transition for early 2026. Net sales guidance remains at $8.4–$8.6 billion.
9 December 2025
··
Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems shares traded at $141.72 on December 9, 2025, after a volatile year that included a 21% surge two weeks prior following an analyst upgrade and positive reimbursement news. Q3 revenue rose 10% to $224.5 million, with net income at $9.9 million and adjusted EPS of $0.38, beating estimates. The company also launched its new Inspire 5 system.
9 December 2025
·
Kontoor Brands (KTB) Stock on December 9, 2025: Q3 Beat, Analyst Upgrades and Volatile Trading Create a 2026 Upside Story

Kontoor Brands (KTB) Stock on December 9, 2025: Q3 Beat, Analyst Upgrades and Volatile Trading Create a 2026 Upside Story

Kontoor Brands shares traded between $75 and $76 on December 9, about 19% below their January high, after falling 3–4% intraday amid weak consumer data. Wells Fargo raised its price target to $100 and reiterated an “overweight” rating. Marshall Wace trimmed its stake following recent gains. Kontoor’s Q3 revenue rose 27% to $853 million, with EPS of $1.44 beating forecasts.
9 December 2025
··
AutoZone (AZO) Stock Plunges After Q1 2026 Earnings Miss — What Investors Need to Know Today

AutoZone (AZO) Stock Plunges After Q1 2026 Earnings Miss — What Investors Need to Know Today

AutoZone shares fell about 7–8% Tuesday after fiscal Q1 2026 results missed profit estimates, making it the S&P 500’s worst performer. Net sales rose 8.2% to $4.63 billion, but net income dropped to $530.8 million from $564.9 million a year earlier. Diluted EPS came in at $31.04, below analyst forecasts and marking a sixth straight quarterly miss. Trading volume surged as investors reacted to weaker margins and guidance.
9 December 2025
··
Stock Market Today: Wall Street Rises as Fed Cut Looms, Nvidia Gets China Nod

Stock Market Today: Wall Street Rises as Fed Cut Looms, Nvidia Gets China Nod

U.S. stocks rose slightly on December 9, 2025, as the Federal Reserve began a meeting expected to produce a quarter-point rate cut. Nvidia shares moved after President Trump approved conditional H200 AI chip exports to China. The Dow gained 0.1%–0.3%, while the S&P 500 and Nasdaq were up about 0.2%. A bidding war for Warner Bros. added volatility.
9 December 2025
····
1 … 993 994 995 996 997 … 1,348

Stock Market Today

  • UiPath PATH Reports Strong Fiscal Year-End with Robust Revenue and Profitability Gains
    March 13, 2026, 3:24 PM EDT. UiPath PATH closed its fiscal year with revenue of $481 million in Q4, up 14% year-over-year, and annual revenue rising 13% to $1.611 billion. The company achieved full-year GAAP profitability for the first time, reporting $104 million net income in Q4 and $282 million annually. Annual recurring revenue (ARR) reached $1.853 billion, up 11% year-over-year, reflecting steady demand for automation software amid accelerating digital transformations. PATH also generated strong cash flows, with $182 million in adjusted free cash flow in Q4 and closed the quarter with about $1.7 billion in cash and no debt. A $1 billion share repurchase was completed, with an additional $500 million approved. These results highlight PATH's improving financial strength and operational discipline as it scales the business.
Go toTop